Related Experiment Video

Updated: Apr 21, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.7K

Glucokinase MODY and implications for treatment goals of common forms of diabetes

Ramzi A Ajjan1, Katharine R Owen

  • 1LIGHT Laboratories, University of Leeds, Leeds, UK, R.Ajjan@leeds.ac.uk.

Current Diabetes Reports
|October 27, 2014
PubMed

Insights

Glucokinase mutations (GCK-MODY) offer insights into diabetes treatment. This review explores using GCK-MODY as a model to refine glycated haemoglobin (HbA1c) targets, potentially minimizing adverse effects of intensive glucose lowering.

Area of Science:

  • Endocrinology
  • Metabolic Disorders
  • Genetics

Background:

  • Current diabetes treatment goals focus on reducing vascular complications via glycated haemoglobin (HbA1c) targets.
  • These targets lack consideration for adverse effects linked to achieving normal HbA1c levels.
  • Glucokinase mutations (GCK-MODY) cause mild hyperglycemia with minimal vascular issues.

Purpose of the Study:

  • To evaluate the potential of GCK-MODY as a paradigm for optimizing diabetes treatment goals.
  • To explore the clinical applicability of GCK-MODY insights for managing diabetes.
  • To identify limitations and considerations for using GCK-MODY as a therapeutic model.

Main Methods:

  • Review of existing epidemiological and clinical data on GCK-MODY.
  • Analysis of vascular complication rates in GCK-MODY patients compared to general diabetes populations.
  • Discussion of the biological mechanisms underlying GCK-MODY's protective effects.

Main Results:

  • GCK-MODY patients exhibit significantly lower rates of vascular complications, comparable to non-diabetic individuals.
  • This suggests that a less stringent HbA1c target may be safe and effective.
  • The study highlights the role of glucokinase activity in glucose homeostasis and complication prevention.

Conclusions:

  • GCK-MODY serves as a valuable natural experiment for reassessing diabetes treatment targets.
  • Translating GCK-MODY findings could lead to safer, more individualized HbA1c goals.
  • Further research is needed to address the nuances of applying this paradigm across diverse diabetic populations.

More Related Videos

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

1.2K
A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination12:33

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination

Published on: June 25, 2014

64.9K

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
982
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
997
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.8K
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose...
2